Eli Lilly and Stock LLY · Forecast & Analysis
Heads-up: USD Michigan Consumer Sentiment is due in 21 h (high impact). The outlook can shift noticeably around it.
Eli Lilly is bullish on the back of its obesity pipeline: strong Phase 3 data for the oral GLP-1 Foundayo in sleep apnea and fresh ObesityWeek results expand future revenue options. The view rests on news alone; no LLY price history is available here.
News situation · 20 items / 30 D
17 of 20 straight from the issuer or regulator
Outlook for Eli Lilly and Company
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
No price statement: there is no price data for this asset. Based on 20 news items.
What drives it
- Foundayo, the oral GLP-1, met its Phase 3 endpoint in sleep apnea; an FDA submission is planned by year-end.
- ObesityWeek data for retatrutide and the oral EloraTZP showed deep weight loss and large sleep apnea benefit.
- A Hims & Hers distribution deal opens a direct-to-consumer channel for Zepbound and Foundayo.
What argues against it
- Side-effect discontinuations ran well above placebo in a subgroup of the sleep apnea trial.
- The planned FDA submission is not yet filed, and approval timing remains uncertain.
- The investigational medicines behind the new data cannot yet be sold, so revenue stays distant.
- Heavy US data in the coming days, from GDP to PCE inflation, may sway the stock through the macro backdrop.
What would change the picture
- A year-end FDA filing for the oral GLP-1 in sleep apnea, or a delay in it, would reshape the outlook.
- Phase 3 results for retatrutide, still investigational, landing clearly better or worse than expected.
Coming up
- US: Michigan Consumer Sentiment · expected 51.0, previous 51.0
- US: CB Consumer Confidence Index · expected 91.5, previous 91.7
- US: Jobless claims, PCE price index, GDP · expected 3.1%, previous 3.1%
Economic data for LLY
Full calendarRecently released
- TodayUSDInitial Jobless Claims●●●
- TodayUSDPhiladelphia Fed Manufacturing Index●●●Forecast 32.2Previous 20.9
- November 18, 2026USDEIA Crude Oil Stocks Change●●●Actual 3.380MForecast -0.309MPrevious 4.657M
- November 17, 2026USDCore Retail Sales m/m●●●Actual 0.6%Forecast 0.7%Previous 1.1%
- November 17, 2026USDRetail Sales m/m●●●Actual 0.2%Forecast 0.3%Previous 0.8%
Coming up
- TomorrowUSDMichigan Consumer Sentiment●●●Forecast 51.0Previous 51.0in 21h
- November 24, 2026USDCB Consumer Confidence Index●●●Forecast 91.5Previous 91.7in 4 days
- November 25, 2026USDInitial Jobless Claims●●●in 5 days
- November 25, 2026USDCore PCE Price Index y/y●●●Forecast 3.1%Previous 3.1%in 5 days
- November 25, 2026USDCore PCE Price Index m/m●●●Forecast 0.3%Previous 0.3%in 5 days
- November 25, 2026USDGDP Sales q/q●●●Forecast 1.7%Previous 1.7%in 5 days
- November 25, 2026USDGDP q/q●●●Forecast 3.4%Previous 3.4%in 5 days
- November 25, 2026USDDurable Goods Orders m/m●●●Forecast -0.7%Previous 1.8%in 5 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about LLY
Frequently asked questions about Eli Lilly and Company
What is the strongest recent news for Eli Lilly and LLY?
The Phase 3 ATTAIN-OSA readout: the oral GLP-1 Foundayo cut sleep apnea severity by up to 43.8% and body weight by roughly 11.5% at 52 weeks, and Lilly plans to file with the FDA for this new use by the end of 2026. That opens a large market beyond obesity for an already approved pill.
Why didn't the strong ObesityWeek data move LLY much?
Conference presentations are largely anticipated: the EloraTZP and retatrutide results were expected strengths of a known pipeline, and neither drug can legally be sold yet. Positive but familiar data tend to support the story rather than trigger a sharp move.
What would change the bullish view on Eli Lilly?
Watch the planned FDA submission for the oral GLP-1 in sleep apnea by year-end: a filing supports the story, a delay weakens it. Retatrutide's Phase 3 progress matters too, since manufacturing capacity is already being built for it. Any safety setback would also weigh on the picture.
📝 Overview Generated automatically
LLY has been the subject of 73 signals across 73 articles in the last 365 days. Sentiment skews Bullish (45%).
Breakdown: 33 bullish, 7 bearish, 33 neutral.
Most-cited catalysts: Supreme Court denies appeal on $194 million Medicaid penalty (1×), Immediate earnings charge in upcoming quarter (1×), Validation of oral GLP-1 category by EMA (1×). Most-cited risk factors: Lilly's strong cash position may mitigate market reaction (1×), Ruling was expected and priced in (1×), Novo's oral Wegovy may establish strong brand loyalty before Lilly's launch (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.